it accelerates the body's natural fat burning instead of suppressing appetite. Built to extend what GLP‑1 therapies achieve: greater weight loss, preserved muscle and lasting results.
MT-1101 selectively reaches mitochondria and indirectly accelerates their natural fat-burning process – increasing energy expenditure while avoiding the safety limitations associated with earlier approaches.
Learn How It Works
simple oral dosing, on its own or alongside injectable GLP‑1s.
up to 27% in preclinical models, not appetite-driven.
weight loss comes from fat, not muscle.
adds >50% to GLP‑1 weight loss and holds weight after GLP‑1 treatment stops.
Phase 1b planned for early 2027.